Recombinant Human SKIV2L Protein, N-His

Description of Recombinant Human SKIV2L Protein, N-His

Introduction

Recombinant Human SKIV2L Protein, also known as Superkiller Viralicidic Activity 2-like protein, is a crucial component of the SKI complex involved in RNA degradation. This protein is encoded by the SKIV2L gene and is highly conserved among eukaryotes. Recombinant Human SKIV2L Protein is widely used in various research applications due to its essential role in RNA metabolism and its potential as a therapeutic target.

Structure of Recombinant Human SKIV2L Protein

Recombinant Human SKIV2L Protein is composed of 1,235 amino acids with a molecular weight of approximately 140 kDa. It contains multiple domains, including an N-terminal DUF111, a central RNA helicase domain, and a C-terminal DUF1795. The RNA helicase domain is responsible for the ATP-dependent unwinding of RNA molecules, while the DUF1795 domain has been shown to interact with other components of the SKI complex.

Activity of Recombinant Human SKIV2L Protein

Recombinant Human SKIV2L Protein plays a crucial role in RNA degradation through its involvement in the SKI complex. This complex is responsible for targeting and degrading aberrant or unnecessary RNA molecules, such as viral RNA, in the cell. The ATP-dependent RNA helicase activity of SKIV2L is essential for the efficient degradation of these RNA molecules. Additionally, SKIV2L has been shown to interact with other proteins involved in RNA metabolism, indicating its potential role in regulating RNA processing and stability.

Application of Recombinant Human SKIV2L Protein

1. RNA degradation studies: Recombinant Human SKIV2L Protein is widely used in studies of RNA degradation pathways. Its ATP-dependent RNA helicase activity makes it a valuable tool for investigating the mechanisms of RNA degradation and the role of the SKI complex in this process.

2. Antiviral research: As Recombinant Human SKIV2L Protein is involved in targeting and degrading viral RNA, it has potential applications in antiviral research. By understanding the role of SKIV2L in viral RNA degradation, researchers can develop targeted therapies to inhibit viral replication and infection.

3. Therapeutic target: Mutations in the SKIV2L gene have been linked to various diseases, including immunodeficiency and neurological disorders. Recombinant Human SKIV2L Protein can be used to study the effects of these mutations and potentially develop targeted therapies for these diseases.

4. Diagnostic tool: SKIV2L has been identified as a potential biomarker for various diseases, including cancer. Recombinant Human SKIV2L Protein can be used in diagnostic assays to detect the presence of SKIV2L in patient samples, aiding in disease diagnosis and monitoring.

5. Production of monoclonal antibodies: Recombinant Human SKIV2L Protein can be used as an antigen to produce monoclonal antibodies specific to SKIV2L. These antibodies can then be used in various research and diagnostic applications, such as Western blotting and immunohistochemistry.

Conclusion

Recombinant Human SKIV2L Protein is a crucial component of the SKI complex involved in RNA degradation. Its structure, activity, and potential applications make it a valuable tool for studying RNA metabolism and its role in various diseases. As research in this field continues to advance, the use of Recombinant Human SKIV2L Protein is likely to increase, contributing to a better understanding of RNA degradation and its implications in human health.